Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.74%306.720.0%$5256.57m
BNTXBioNTech SE 3.17%344.060.0%$1596.83m
NVAXNovavax, Inc. -0.92%160.4878.2%$831.00m
AMGNAmgen, Inc. 0.63%202.441.4%$596.39m
GILDGilead Sciences, Inc. -0.16%69.561.0%$505.86m
REGNRegeneron Pharmaceuticals, Inc. 0.18%635.162.7%$472.48m
VRTXVertex Pharmaceuticals, Inc. -0.31%203.811.9%$464.56m
LGVNLongeveron Inc. 11.78%20.120.0%$429.77m
ILMNIllumina, Inc. -2.85%347.283.3%$324.28m
SNSSSunesis Pharmaceuticals, Inc. -4.21%4.100.7%$286.61m
BIIBBiogen, Inc. -2.01%223.921.8%$276.52m
INCYIncyte Corp. -1.28%65.782.4%$150.25m
SGENSeagen Inc. -5.00%150.745.8%$149.09m
EXASEXACT Sciences Corp. -4.94%76.5918.0%$140.15m
OCGNOcugen, Inc. -8.72%5.760.0%$139.18m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.